File downloaded on 2025-12-01

Source URL: https://medicines.health.europa.eu/veterinary/en/600000089279

RILEXINE DC 375 MG INTRAMAMMARY SUSPENSION FOR DRY COWS

Authorised

Cephalexin benzathine

Product identification

Medicine name:

Cefalexin "Virbac" 375 mg intramammær suspension
RILEXINE DC 375 MG INTRAMAMMARY SUSPENSION FOR DRY COWS

Active substance:

Cephalexin benzathine

Target species:

Cattle (dry cow)

Route of administration:

Intramammary use

Product details

Active substance and strength:

Cephalexin benzathine 500.00 milligram(s) / 1.00 Syringe

Pharmaceutical form:

Intramammary suspension

Withdrawal period by route of administration: Intramammary use:

Cattle (dry cow)

- Meat and offal. 4 day Meat and offal: 4 days
- Milk. 43 day 42.5 days after treatment when dry period is 42 days or less
- Milk. 12 hour 12 hours after calving when dry period is more than 42 days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ51DB01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Denmark

Package description:

Box of 12 x 8g intramammary syringes and 12 cleaning towels

Box of 60 x 8g intramammary syringes and 60 cleaning towels

Box of 24 x 8g intramammary syringes and 24 cleaning towels

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder: Virbac
Marketing authorisation date: 12/09/2022
Manufacturing sites for batch release: Haupt Pharma Latina S.r.l. Virbac
Responsible authority: Danish Medicines Agency
Authorisation number: 65695
Date of authorisation status change: 12/09/2022
Reference member state: France
Procedure number: FR/V/0438/001
Concerned member states: Austria Belgium Bulgaria Croatia Czechia Denmark Estonia Finland Germany Hungary Ireland Italy Latvia Lithuania Netherlands Poland Portugal Romania Slovakia Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to $\underline{www.adrreports.eu/vet}$

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.